Plus Therapeutics is pleased to announce the receipt of a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), the world’s second-largest public cancer research funding agency. This payment is part of the $17.6 million grant previously awarded to support the Company’s clinical development of REYOBIQ™ (rhenium Re186 obisbemeda) for the treatment of leptomeningeal metastases (LM).
This non-dilutive funding continues to provide critical support for our ReSPECT-LM trial, which is focused on optimizing dosing for REYOBIQ in patients with LM—a rare and aggressive complication of cancers such as breast cancer, lung cancer, and melanoma.
“This milestone from CPRIT represents continued confidence in our science and mission to address significant unmet needs in neuro-oncology,” said Dr. Marc Hedrick, President and CEO of Plus Therapeutics.
About the ReSPECT-LM Trial
The ReSPECT-LM trial is evaluating intrathecal REYOBIQ™, a novel targeted radiotherapeutic, for its safety and efficacy in treating patients with leptomeningeal metastases. Building on promising results from the Phase 1 single-dose escalation study, the current dose-optimization trial is aligned with the FDA’s Project Optimus initiative and is designed to determine the ideal therapeutic regimen for a future registrational study.
To learn more about participation in the trial, please visit:
respect-trials.com/lm
Or contact: respect@plustherapeutics.com
Read the Full Press Release
Click here to view the official announcement
About CPRIT
The Cancer Prevention and Research Institute of Texas is a state agency committed to funding innovative cancer research and prevention programs. With more than $3 billion in awarded grants, CPRIT continues to be a driving force in advancing cancer care and discovery.
Learn more about Plus Therapeutics:
plustherapeutics.com
respect-trials.com
#PSTV #CPRIT #LeptomeningealMetastases #BrainCancer #NeuroOncology #ClinicalTrials #TargetedRadiotherapy #CancerResearch #REYOBIQ #ReSPECTLM #BreastCancer #LungCancer #Melanoma #ProjectOptimus
Recent Comments